Alerta

COMPOSITIONS AND METHODS FOR THREE-DIMENSIONAL SPATIAL BIOMOLECULE IDENTITY AND ABUNDANCE ASSESSMENT

Resumen de: US20260259202A1

0000 Proper functioning of the human body relies on the organization of cells in 3D space. A cell's function and fate are determined by its biomolecule composition and 3D environment. The spatial identification of proteins, RNAs, DNAs, and other biomolecules in a tissue thus provides a powerful map to decipher how cells build tissues and become diseased. Thus, described herein are methods and compositions for assessing biomolecule identity (the present invention features methods and compositions for assessing biomolecule identity (e.g., genes (DNA, RNA), DNA and RNA modifications, proteins, protein modifications, lipids, sugars, metals), and abundance (e.g., RNA expression levels, protein translation levels) in a 3D tissue sample.

METHODS FOR DETECTING THE PRESENCE OF AT LEAST ONE MISFOLDED FORM OF SOD1 IN A BIOLOGICAL SAMPLE

Resumen de: US20260258472A1

Disclosed herein are methods for detecting the presence of at least one misfolded form of human Superoxide Dismutase 1 (SOD1) in a biological sample obtained from a human subject. In some aspects, the subject is suspected of having, or has, one or more neurodegenerative diseases, such as, for example, Amyotrophic Lateral Sclerosis, Parkinson's disease, or Alzheimer's disease.

FATIGUE SYNDROME SIGNATURES AND METHODS OF TREATMENT

Resumen de: US20260259229A1

A common molecular signature of elevated oxidative stress is detected in blood samples from individuals with fatigue syndromes, including LC, ME-CFS, and lupus patients reporting fatigue. Analysis can be performed with one or more of flow cytometry, bulk RNA-seq analysis, mass spectrometry, and systems chemistry analysis. Elevated reactive oxygen species (ROS) were found, as well as differences in glutathione ROS clearance pathways and markers of oxidative damage.

ENGINEERED EFFECTOR PROTEINS, COMPOSITIONS, SYSTEMS AND METHODS OF USE THEREOF

Resumen de: US20260259201A1

Provided herein are compositions, systems, and methods comprising effector proteins, and uses thereof. These effector proteins may be characterized as CRISPR-associated (Cas) proteins. Various compositions, systems, and methods of the present disclosure may leverage the activities of these effector proteins for the editing, detecting and/or engineering of nucleic acids.

THERAPEUTIC COMPOSITIONS COMPRISING POOLED, CULTURE-EXPANDED HUMAN UMBILICAL CORD DERIVED MESENCHYMAL STROMAL CELLS

Resumen de: WO2025179269A1

The disclosure provides a therapeutic composition comprising pooled, culture-expanded human umbilical cord-derived mesenchymal stromal cells (hucMSCs) derived from at least four and up to twelve donors, which can be reproduced with batch to batch consistency. These cells exhibit consistent marker expression profiles, enhanced and consistent secretion of therapeutic factors, and potent immunomodulatory activities after at least ten to thirty population doublings. The composition, formulated with a pharmaceutically acceptable carrier, is designed for clinical applications addressing inflammatory, immune, and degenerative conditions.

TRAINING AND USE OF MACHINE-LEARNING MODELS FOR PREDICTING BIOLOGICAL CONDITIONS USING VOLATILE ORGANIC COMPOUNDS

Resumen de: WO2025179149A1

Provided herein are methods and systems for diagnosing pathological conditions using machine learning and artificial intelligence models. An exemplary method can include loading an abundance matrix that represents mass spectrometry reads of a sample of a plurality of volatile organic compounds (VOCs) extracted from a biological sample. The abundance matrix can represent each of the plurality of VOCs in a mass-to-charge ratio dimension, an abundance dimension, and a retention time dimension. The method can include providing the abundance matrix to a machine-learning model. The machine- learning model can be trained on abundance matrixes of biomarkers of VOCs collected from healthy and diseased subjects. The method can include receiving, from the machine-learning model, a prediction of a state of a disease state.

MEASURING REDOX CHANGES IN PLASMA PROTEINS

Resumen de: US20260259219A1

Provided is a method for measuring proteomic cysteine redox status in a sample obtained from a bodily fluid of a subject, the method comprising: (i) providing said sample, wherein the sample comprises a plurality of different proteins that comprise cysteine residues, a proportion of which are in reduced form and a proportion of which are in reversibly oxidised form; (ii) contacting the sample with a first label that selectively labels the reduced cysteine thiols of the plurality of different proteins; (iii) contacting the sample with a reducing agent that reduces the reversibly oxidised cysteine residues to form reduced cysteine thiols; (iv) contacting the sample with a second label that labels the reduced cysteine thiols formed in step (iii), wherein the second label is distinguishable from the first label by mass spectrometry, (v) processing the sample for analysis by mass spectrometry; and (vi) analysing the sample by mass spectrometry to measure at least the relative abundance of identified peptides labelled with the first label and corresponding identified peptides labelled with the second label, thereby providing a measure of the proteomic cysteine redox status of the sample. The invention also provides related methods for biomarker discovery and for predicting presence of a liver disease and/or cancer, such as hepatocellular carcinoma (HCC) in a subject.

Fibroblast Activation Markers and TGFBI in Therapy

Resumen de: US20260258118A1

0000 The present invention relates to a method for detecting markers of fibroblast activation in a patient by sandwich immunoassay to identify patients, particularly cancer patients who would benefit from anti-TGFβI therapy. The markers of fibroblast activation may be selected from the N-terminal pro-peptide of Collagen III (Pro-C3), the N-terminal pro-peptide of Collagen VI (Pro-C6), the N-terminal pro-peptide of Collagen I (Pro-C1) and/or an internal sequence in the N-terminal region of type 3 collagen (P3NP). The invention also provides an anti-TGFβI therapy for use in the treatment of cancer and/or fibrosis.

METHODS FOR ASSESSING NEUROLOGICAL DISORDERS BASED ON SOMATOSTATIN POSITIVE INTERNEURON LEVELS

Resumen de: WO2026181008A1

The invention provides methods of assessing abundance of GABAergic somatostatin positive interneurons (SST+ cells) in living brain tissue of a subject by calculating a polygenic risk score using genomic variants of genes co-expressed with SST mRNA and their cis expression quantitative trait loci (cis-eQTLs); or where the genomic variants associated with SST+ cell abundance are variants directly associated with inter-individual variability in SST cell type proportions estimated from bulk RNA-seq data. Also provided are related diagnostic methods.

ＰＡＤ４調節剤のシトルリン化および活性を評価する方法

Resumen de: CN122162053A

The present application relates to methods for quantifying citrullination and methods that can be used to assess the activity of agents including, for example, PAD4 (peptidyl arginine deiminase 4) modulators, such as small molecules or antibodies. In certain embodiments, the methods comprise assessing citrullination of one or more citrullination sites on a protein or peptide fragment thereof present in a biological sample.

METHODS OF USING NEUROFILAMENT LIGHT CHAIN IMMUNOASSAYS

Resumen de: WO2025090763A1

Methods, kits and compositions of detecting analytes, typically analytes relevant to neurodegenerative diseases such as neurofilament light chain, in a sample are described herein using chemiluminescent labels. Solid supports, reagents, and compounds for use in these methods are also described. Typically, the methods involve specific assay formats which provide the requisite high resolution for detecting low concentrations of analytes in samples and may be used in positions of the healthcare ecosystem close to the patient. These methods, systems, and apparatuses may afford early detection and prognosis of a wide variety of neurodegenerative diseases such as Alzheimer's disease and multiple sclerosis.

外泌体ANXA7在阿尔茨海默病诊断、药物筛选及治疗中的应用

Resumen de: CN122671656A

本发明公开了一种外泌体标志物及其在阿尔茨海默病诊断和治疗中的应用。本发明首次发现，AD患者外周血外泌体中ANXA7蛋白水平显著升高，且其诊断效能良好。本发明还首次揭示，在AD病理条件下，Aβ刺激的小胶质细胞通过外泌体将ANXA7递送至神经元，ANXA7进入神经元后诱导细胞凋亡和氧化应激，从而加速AD进展；使用外泌体抑制剂GW4869或敲低小胶质细胞ANXA7表达可显著减轻神经元损伤。基于上述发现，本发明提供了检测外泌体中ANXA7蛋白水平的试剂在制备AD诊断试剂盒中的应用，以及降低ANXA7表达或活性的物质、抑制外泌体分泌的物质在制备治疗AD的药物中的应用。本发明为AD的早期诊断和靶向治疗提供了新的分子标志物和干预策略。

CLOCK蛋白在调控T-2毒素致阿尔茨海默症关键因子表达中的应用

Resumen de: CN122664983A

本发明涉及生物医药技术领域，具体公开了CLOCK蛋白在调控T‑2毒素致阿尔茨海默症关键因子表达中的应用，其技术要点为：本发明通过T‑2毒素诱导的SH‑SY5Y细胞模型发现：T‑2毒素可诱导721个差异表达基因，显著富集于p53信号通路及昼夜节律通路；T‑2毒素使CLOCK蛋白节律参数发生改变，中值由0.697升至0.861，峰相位由22.34h偏移至7.18h，并诱导p53延迟性持续激活（12h达峰值2.31倍）；CLOCK与p53存在双向调控，形成CLOCK‑p53信号轴；该信号轴通过驱动细胞衰老程序（SA‑β‑gal阳性面积24h达25.13%）介导AD关键因子稳态失衡，表现为APP下降（0.53倍）及p‑Tau（1.19倍）、T‑Tau（1.35倍）升高；CLOCK抑制剂CLK8可减轻Tau异常及衰老表型。本发明为AD防治提供了新靶点。

一种快速检测微量血液样本中ApoE的微针贴片及其制备方法与应用

Resumen de: CN122671666A

0001 本发明涉及一种快速检测微量血液样本中ApoE的微针贴片及其制备方法与应用，属于生物检测技术领域。本发明通过将微针贴片等离子处理后，包被ApoE捕获蛋白，获得快速检测微量血液样本中ApoE的微针贴片。本发明通过等离子体技术对微针表面进行处理，使其获得亲水性，从而可以包被特定蛋白，提高了对捕获蛋白的包被能力，增加了检测的灵敏度和准确性，且制备简单，成本可控。本发明获得的微针贴片用于检测ApoE，不仅具备传统血检的高灵敏度和高准确性，还比传统血检所需血液样本量大大减少，无需静脉抽血，可采用指血检测。相较于现有微针检测技术，本发明为血液样本定量结果，检测结果更可靠。

胰岛素受体INSR-α作为治疗靶点的应用

Resumen de: CN122665107A

本发明属于生物医药领域，具体涉及胰岛素受体INSR‑α作为治疗靶点的应用。本发明提供了特异性结合胰岛素受体INSR‑α的抗体或胰岛素受体INSR‑α信号拮抗剂在制备用于预防和/或治疗肝纤维化的药物中的应用。同时，本发明还提供了一种筛选由MASLD/MASH引起的肝纤维化的药物的方法，所述方法包括，将待测物质给予施用对象；检测施用对象中肝星状细胞的活性；以及判断所述待测物质是否为候选药物的步骤。本发明通过实验证明，通过使用胰岛素受体INSR‑α的中和抗体结合INSR‑α或其信号拮抗剂抑制HSCs的活化，可减轻MASLD/MASH的肝纤维化进程。因此，本发明为由MASLD/MASH引起的肝纤维的治疗提供新途径。

ＩＬ－１１抗体

Resumen de: SA520420801B1

Provided a re antigen-binding molecules capable of binding to IL-11, and methods of medical treatment and prophylaxis using the same. Fig 1.

用于增强过继性细胞疗法的方法和组合物

Resumen de: WO2025122947A1

Aspects of the disclosure include methods of monitoring and/or prognosing an adoptive cell therapy in a subject, comprising determining a level of endogenous SCF in a biological sample from the subject, in which the detection of a presence, absence, and/or amount of endogenous SCF is informative of the in vivo activation and/or expansion of the adoptive immune cells, the anti-tumor effect of the adoptive cell therapy, and/or the need for a treatment modification and/or extension. The disclosure also provides a method of treating a disease by administering at least one c-kit agonist (e.g., SCF) simultaneously or sequentially with an adoptive cell therapy.

抗ＩＬ－５抗体及びその使用

Resumen de: MX2026001711A

The invention provides novel anti-IL-5 proteins, antibodies and IL-5 binding fragments thereof, which inhibit association of IL-5 with IL-5 receptor and are suitable for administration to a human or feline subject. The invention provides novel compositions and methods of treating, alleviating the symptoms of, or preventing, lung diseases, cardiovascular diseases, cancers, metabolic diseases, neurological diseases, and infectious diseases, comprising administering an effective amount of an anti-IL-5 protein, antibody, or fragment thereof. The methods and compositions are used to treat or prevent IL-5-related disorders.

一段階ナノスケール膨張顕微鏡法

Resumen de: WO2025026904A1

The present invention relates to a microscopy method for obtaining a high-resolution image of a biological sample comprising a substance to be analyzed, wherein an image sequence is obtained by expansion microscopy comprising the steps: g. providing a biological sample, h. mixing said biological sample with a swellable material and forming bonds, preferably covalent bonds, between said substance to be analyzed and the swellable material, thereby forming a mixture, i. fragmenting said substance to be analyzed, j- expanding the mixture comprising said swellable material and said fragmented substance to be analyzed, k. staining the sample either before or after steps (a), (b), (c), or (d) and imaging the obtained mixture under an optical microscope equipped with a camera or a resonant scanner. It also refers to compounds and stabilization chambers for use in such a method.

脳タウ又はアミロイドレベルを予測するためのシステム及び方法

Resumen de: AU2024293997A1

A machine learning model can be trained to predict brain tau or amyloid β status of a patient using, at least in part, biomarker data of the patient. The brain tau or amyloid β status can include one or more continuous-valued brain tau or amyloid β levels and/or concern brain tau or amyloid β levels in multiple regions of the brain of the patient. A prediction of brain tau or amyloid β status of the patient can be generated by applying the subject data of the patient to the machine learning model. The operations can further include providing the prediction of brain tau or amyloid β status of the patient. The machine learning model be used in selection of patients for treatment with an anti-tau therapy and/or an anti-amyloid therapy, in treatment of patients having or suspected of having Alzheimer's Disease (AD), or in monitoring of AD treatment efficacy.

用于测量补体活化的方法和材料

Resumen de: AU2025215582A1

The present disclosure provides, e.g., signature peptide compounds corresponding to various full-length protein components of the complement enzymatic cascade (e.g., C1q, C1s, C3, C3p, C4, C4p, C5, C5p, FB, and FBp). In one aspect, the invention relates to using these signature peptides for measuring and/or monitoring activation of the complement pathway, e.g., in clinical samples, such as plasma, serum, CSF, aqueous humor, or vitreous humor.

１５－ヒドロキシプロスタグランジンデヒドロゲナーゼ阻害剤により対象を処置するための方法および組成物

Resumen de: WO2025042785A1

Provided herein are compositions and methods for reducing levels of at least one biomarker in a subject. The at least one biomarker may include p75ECD, PGE-MUM, or both. In some cases, the compositions and methods provided herein involve administering to a subject an amount of a 15-hydroxyprostaglandin dehydrogenase (15-PGDH) inhibitor effective to reduce levels of the at least one biomarker in the subject.

アルツハイマー病および他の疾患におけるアミロイドβペプチドプロテイノペニアを予防および／または処置するための組成物および方法

Resumen de: CN122341632A

The present invention provides material compositions and/or methods useful for the prevention and/or treatment of protein depletion (proteopenia), comprising material compositions that retain the natural function of peptides/proteins while limiting and/or preventing amyloid formation and/or aggregation of the peptides/proteins. Also provided are material compositions and formulations for enhancing peptide/protein solubility, stability, cycle time, receptor interaction, brain permeability, CSF half-life, promoting peptide/protein synthesis and purification.

SERPINA3、BACE1或CXCL1对于在制备用于2型糖尿病合并代谢综合征患者相关产品的用途

Resumen de: CN122652049A

0001 本发明提供生物标志物在制备用于对2型糖尿病合并代谢综合征患者进行中医证型分型，和/或,用于评估2型糖尿病合并代谢综合征患者认知功能受损风险的产品中的用途，所述生物标志物选自SERPINA3、BACE1或CXCL1中的一种或多种。血清SERPINA3、BACE1、CXCL1水平与中医证型有关联，为中医辨证论治提供实验室依据，有助于提高中医诊断的准确性和规范性，根据血清指标水平和表征，制定个性化的治疗方案；其次，血清指标对认知功能受损有预测价值，有助于早期识别高危患者，延缓认知功能下降。对于病程较长、血糖控制不佳的患者，可定期检测血清指标水平，结合临床指征，及时给予抗炎、营养神经、改善胰岛素抵抗治疗，保护认知功能。

一种基于化学发光法检测尿液中β-淀粉样蛋白前体片段Aβ的试剂组合

Nº publicación: CN122652033A 28/08/2026

Solicitante:

湖南乾康科技有限公司

Resumen de: CN122652033A

本发明公开了一种基于化学发光法检测尿液中β‑淀粉样蛋白前体片段Aβ的试剂组合。它由试剂R1、试剂R2和试剂R3组成；所述试剂R1用磁珠稀释液将偶联β淀粉样蛋白单克隆抗体的羧基磁珠按1:30‑1:60的体积比例稀释而成；所述试剂R2是用吖啶酯稀释液将吖啶酯标记的人源化IgG1单克隆抗体稀释至发光值控制在6000万以上而成；所述试剂R3是用阻断剂稀释液将阻断剂稀释至阻断剂的浓度为8ug/mL以上；所述阻断剂为鼠IgG+HAMA和RF特异性抗体。